{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017166","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.011050+00:00","generated_at":"2026-06-22T00:45:30.957296+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MaxCyte Q3 revenue up 5% to $10.6M; core business grows 22%; net loss widens to $6.4M","bullets":["Total revenue $10.6M (+5% YoY); core business revenue $9.9M grew 22% led by cell therapy +27%.","Net loss widened to $6.4M from $2.7M; EBITDA loss $7.1M vs $2.4M loss a year ago.","Cash and equivalents $232.9M; operating expenses rose to $17.0M from $11.6M on staffing and R&D.","Reiterated FY2022 guidance: core revenue growth ~30%, SPL program revenue ~$4.0M.","Cell therapy revenue $7.9M (+27%), drug discovery $2.0M (+4%); SPL revenue fell 62% to $0.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017166","json":"https://secwatch.observer/filing/0001558370-22-017166.json","markdown":"https://secwatch.observer/filing/0001558370-22-017166.md","text":"https://secwatch.observer/filing/0001558370-22-017166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837022017166/0001558370-22-017166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837022017166/mxct-20221109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:45:30.957296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f5bc2d63cf977986eb34bb1691e4ad3008f8e5b","claim":"MAXCYTE, INC. reported financial results for the nine months ended September 30, 2022.","evidence_excerpt":"announcing its financial results for the quarter and nine months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837022017166/0001558370-22-017166-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a31991cc0c48622248726452396e0bcd73451289","claim":"MAXCYTE, INC. reported the third quarter ended September 30, 2022 results: revenue $10.6 million, net income $6.4 million. Guidance reaffirmed.","evidence_excerpt":"Total revenue of $10.6 million in the third quarter of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837022017166/0001558370-22-017166-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$10.6 million"},{"label":"Net income","value":"$6.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}